About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals is a company based in Dublin (Ireland) founded in 1996 by Mauro Ajani. The company has 321 employees. Cosmo Pharmaceuticals has completed 2 acquisitions, including BioXell and Cassiopea. Cosmo Pharmaceuticals operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, Alcresta and Norgine, among others.
- Headquarter Dublin, Ireland
- Employees 321
- Founders Mauro Ajani
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website cosmopharma.com
- Social LinkedIn X YouTube
- Legal Name Cosmo Pharmaceuticals Nv
Funding Insights of Cosmo Pharmaceuticals
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Cosmo Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2008 | – | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Cosmo Pharmaceuticals
Cosmo Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Invision.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Invision is engaged in providing investment and succession solutions for mid-sized companies. | – | invision.ch | Zug, Switzerland |
Investor details for Cosmo Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cosmo Pharmaceuticals
20 people are tracked at Cosmo Pharmaceuticals (11 in leadership, 4 in board & advisors, 5 in team); the tracked headcount is 321.
| Name | Role | Group |
|---|---|---|
Mauro Ajani | Founder & Chairman | Leadership |
Stefania Pagani | Deputy Chief Scientific Officer | Leadership |
Marco Lecchi | Chief Operating Officer | Leadership |
Roberto Villa | Chief Manufacturing Officer | Leadership |
Alessandro Della Chà | CEO | Leadership |
Davide Malavasi | Qualified Person & Technical Director | Leadership |
Niall Donnelly | CFO | Leadership |
Luigi Longo | Chief Scientific Officer | Leadership |
Maddalena Scampuddu | Head Of It, Security And Compliance | Leadership |
Hazel Winchester | Head of Investor Relations | Leadership |
John O'Dea | Director | Leadership |
Maria Grazia Roncarolo | Non-Executive Director | Board & advisors |
Mauro Severino Ajani | Non-Executive Director, Chairman | Board & advisors |
Kevin Donovan | Non-Executive Director | Board & advisors |
David W. Maris | Non-Executive Director | Board & advisors |
Mara Gerloni | SVP of Preclinical Operations | Team |
Giulio Evangelisti | SVP of Manufacturing, Service & Security, Cosmo Intelligent Medical Devices | Team |
Dariusz Leszek Krajewski | Operations Manager | Team |
Paolo Lanzarotti | R&D Analytical Development Manager | Team |
Andrea Lovati | Quality Assurance Manager | Team |
Complete people profiles for Cosmo Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cosmo Pharmaceuticals
Cosmo Pharmaceuticals is a publicly listed company on the SIX with ticker symbol COPN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Mar 2007
- Listed onSWX: COPN
- Listed entityCosmo Pharmaceuticals NV
- Exchange sectorHealth technology
- ISINNL0011832936
- Share price73.20 CHF · 2026-05-11
- Market capitalisation1,232,523,071.00 CHF
- Price to earnings21.0
- EPS (diluted, trailing year)-0.21 CHF
- Dividend yield2.64%
- Volume (last session)10,144
- Analyst consensusStrong buy
Financials of Cosmo Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 97.6M CHF | -3.4M CHF | 2.2M CHF |
| 2024 | 254.1M CHF | 126.9M CHF | 150.0M CHF |
| 2023 | 90.1M CHF | -10.5M CHF | 7.8M CHF |
| 2022 | 102.5M CHF | 17.3M CHF | 40.2M CHF |
| 2021 | 70.3M CHF | 23.4M CHF | 19.1M CHF |
Detailed financial statements for Cosmo Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cosmo Pharmaceuticals
Cosmo Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioXell and Cassiopea.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical-stage pharma company focused on Italian dermatology treatments. | cassiopea.com | Lainate, Italy | 2009 | Oct 2021 | •••• | |
Italian, clinical stage biopharma developing small molecule and antibody therapeutics for chronic inflammatory and autoimmune diseases | bioxell.com | Segrate, Italy | 2002 | Nov 2009 | •••• |
Complete acquisition details for Cosmo Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cosmo Pharmaceuticals
Competitors of Cosmo Pharmaceuticals
Cosmo Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, Alcresta and Norgine, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. | |
| norgine.com | 1906 | Amsterdam, Netherlands | – | – | Proprietary therapeutic products for gastrointestinal diseases are developed and marketed. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | – | Synbiotics are developed for simulating the gut microbiome. | |
| bauschhealth.com | 1960 | Laval, Canada | – | 808 | Therapeutics for multiple diseases including dermatology and neurology are developed. | |
| calypsobiotech.com | 2013 | – | $36.39M | – | Antibody-based therapeutics are developed for gastrointestinal diseases. | |
| lianbio.com | 1999 | Shanghai, China | $313M | – | Therapeutics for cardiorenal and oncology diseases are developed. |
Detailed competitors of Cosmo Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cosmo Pharmaceuticals
The website of Cosmo Pharmaceuticals (cosmopharma.com) receives about 95.6K visits a month and ranks #186,606 among all websites worldwide, #5,990 in Biotechnology and Pharmaceuticals.
- Monthly visits95.6K
▼ 66.3% vs previous month
- Unique visitors146.2K
per month
- Global rank#186,606
among all websites
- Category rank#5,990
Health · Biotechnology and Pharmaceuticals
- Bounce rate56%
- Pages per visit1.7
- Average visit47 sec
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with Cosmo Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cosmofarma.com | cosmofarma.com | 100% | – | #5,742,823 | – |
| chemopharmaceuticals.com | 99% | – | #4,050,784 | View details | |
| swissbiotech.org | 98% | 63.9K | #658,452 | View details | |
cosmos-pharm.com | cosmos-pharm.com | 76% | – | #9,963,166 | – |
| hairlosscure2020.com | 73% | – | #690,734 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Cosmo Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cosmo Pharmaceuticals
Complete news archive for Cosmo Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cosmo Pharmaceuticals
10 companies that operate in the same segment as Cosmo Pharmaceuticals (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cosmo Pharmaceuticals
Cosmo Pharmaceuticals was founded in 1996 and raised its 1st funding round 12 years after it was founded.
Cosmo Pharmaceuticals is headquartered in Dublin, Ireland.
Cosmo Pharmaceuticals has 321 employees.
Annual revenue of Cosmo Pharmaceuticals is $123.18M as on Dec 31, 2025.
Cosmo Pharmaceuticals was founded in 1996 in Dublin, Ireland, within the pharmaceuticals sector. Therapeutics targeting gastrointestinal diseases are developed, including Aemcolo for inflammatory bowel conditions, Byfavo for sedation in colonoscopy procedures, MethyleneBlue MMX for lesion detection during colonoscopies, and CB-03-10 for solid tumors. Additionally, GI Genius AI-enhanced software is provided to support endoscopy processes.
Cosmo Pharmaceuticals's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Yes, Cosmo Pharmaceuticals is publicly traded on SIX under the ticker symbol COPN.
Cosmo Pharmaceuticals has 1 investor. Key investors include Invision.